Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development.

Epidemiological studies showed that women have a lower bladder cancer (BCa) incidence, yet higher muscle-invasive rates than men, suggesting that estrogen and the estrogen receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), may play critical roles in BCa progression. Using in vitro cell lines and an in vivo carcinogen N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced mouse BCa model, we found that ERβ plays a positive role in promoting BCa progression. Knockdown of ERβ with ERβ-shRNA in ERβ-positive human BCa J82, 647v and T24 cell lines led to suppressed cell growth and invasion.

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

Early studies suggested androgen receptor (AR) splice variants might contribute to the progression of prostate cancer (PCa) into castration resistance. However, the therapeutic strategy to target these AR splice variants still remains unresolved. Through tissue survey of tumors from the same patients before and after castration resistance, we found that the expression of AR3, a major AR splice variant that lacks the AR ligand-binding domain, was substantially increased after castration resistance development.

Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy.

The aim of this study describes the creation of superhigh-magnetization nanocarriers (SHMNCs) comprised of a magnetic Fe(3)O(4) (SHMNPs) core and a shell of aqueous stable self-doped poly[N-(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (∼27.1 wt%) of doxorubicin (DOX). The SHMNCs display superparamagnetic property with a magnetization of 89.

Prognostic value of TNM stage and tumor necrosis for renal cell carcinoma.

Our objective was to assess the value of tumor necrosis and other factors for predicting the outcome of renal cell carcinoma (RCC). Our study comprised 328 RCC patients who were surgically treated at this hospital between 2001 and 2006. The five-year survival data was analyzed using a Kaplan-Meier statistical analysis.

Epstein-Barr virus-infected cell line TCC36B derived from B lymphocytes infiltrating renal pelvis urothelial carcinoma.

Unlabelled: This study reports an initial analysis of an EBV-infected B cell line (TCC36B), established from an urothelial carcinoma (UC) lesion of the renal pelvis.

Materials And Methods: Cytofluorometric and G-banding analyses were performed for phenotyping and cytogenetics. PCR was used to detect EBV DNA, and sequence analysis to investigate mutations and deletions of the latent membrane protein (LMP)-1 gene of EBV.

Epstein-Barr virus DNA load in tumour tissues correlates with poor differentiation status in non-muscle invasive urothelial carcinomas.

Objective: To detect the correlation between the clinical staging, grading and genomic Epstein-Barr virus (EBV) viral numbers in tumour tissues of urothelial carcinoma patients.

Patients And Methods: From June 2004 to May 2008, 60 urothelial carcinoma patients (50 cases of bladder carcinoma and 10 of upper tract urothelial carcinoma (UTUC) were enrolled in the study. Eight patients who underwent transurethral resection of prostate for prostate hyperplasia and two patients receiving nephrectomy for non-function kidney were used as normal controls.

Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer.

A nontoxic drug nanocarrier containing carboxyl groups was successfully developed by mixing magnetic nanoparticles (MNPs) of Fe(3)O(4) with the water-soluble polyaniline derivative poly[aniline-co-sodium N-(1-one-butyric acid) aniline] (SPAnNa) and doping with HCl aqueous solution to form SPAnH/MNPs shell/core. SPAnH/MNPs could be used to effectively immobilize the hydrophobic drug paclitaxel (PTX), thus enhancing the drug's thermal stability and water solubility. Up to 302.

Age-related reference levels of serum prostate-specific antigen among Taiwanese men without clinical evidence of prostate cancer.

Background: To determine the normal distribution of serum prostate-specific antigen (PSA) levels in Taiwanese men without clinical evidence of prostate cancer.

Methods: Between August 2006 and October 2007, healthy Taiwanese men undergoing a routine health examination in our hospital were recruited into the study. All men received a digital rectal examination (DRE) and serum PSA determination and some received a transrectal ultrasound (TRUS).

The impact of regular biopsy in the first cystoscopic follow-up and other predictors on the recurrence of superficial bladder tumors.

Background: To evaluate whether cystoscopic evaluations with bladder biopsy can serve as a significant predictor of superficial bladder tumor recurrence.

Methods: This study examined patients with superficial bladder cancer (Ta/T1). At the first three-month cystoscopic follow-up, subjects were divided into two groups: group 1 received cystoscopic examinations with transurethral bladder biopsy, and group 2 had a cystoscopic examination only.

Mixed germ cell tumor metastatic to the skin: case report and literature review.

Background: Testicular cancer is the most common cancer for males aged 15 to approximately 35 years old. The initial presentation is typically an asymptomatic enlarged testicle. The retroperitoneum is the most common metastatic area.

Urinary fluorescence in situ hybridization assay for detecting urothelial carcinoma in Taiwanese patients.

Objectives: To investigate the cytogenetic marker detected by fluorescence in situ hybridization (FISH; UroVysion, Vysis, Inc., Abbott Laboratories, Des Plaines, IL, USA) in the diagnosis of bladder cancer and upper tract urothelial carcinoma (UC) in Taiwanese patients, as FISH has been used in Western countries for detecting UC, but there are limited results in Asian populations.

Patients And Methods: We analysed polyploidy of chromosome 3, 7, 17 and aneuploidy of chromosome 21, using uroepithelial cells collected at the first void or by instrumental extraction of urine, for bladder cancer, and shedding cells from the upper tract flushed by normal saline via ureteric catheterization or ureterorenoscopy.

Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes.

In renal cell carcinoma (RCC), HLA class I downregulation has been found in about 40% of the lesions examined. Since only scanty information is available about the molecular basis of these defects, we have investigated the mechanism(s) underlying HLA class I antigen downregulation or loss in six RCC cell lines. Five of them express HLA class I antigens although at various levels; on the other hand, HLA class I antigens are not detectable on the remaining cell line, the RCC52 cell line, belonging to a sarcomatoid subtype, even following incubation with IFN-gamma.

Bladder leiomyoma with right hydronephrosis.

The authors describe one female patient with leiomyoma of the bladder who presented with female pseudoprostate and right hydronephrosis. A computed tomography (CT) of the pelvis revealed a soft tissue mass, circumferential and heterogenous in appearance with some calcification inside the mass. Bladder leiomyoma might be one of the differential diagnoses with CT imaging findings of female pseudoprostate.